CLEVELAND, Ohio– The Food and Drug Administration (FDA) has issued a warning for patients who take the multiple sclerosis drug fingolimod, sold under the brand name Gilenya by the Swiss pharmaceutical company Novartis after a patient taking the drug developed a rare but serious brain infection.
Gilenya was FDA–approved in 2010 for adults with relapsing forms of MS to reduce the frequency of relapses and to delay physical disability. Multiple sclerosis affects more than 2 million people worldwide.
